Petros Grivas, MD, PhD / Neal D. Shore, MD, FACS - Personalizing Bladder Cancer Care in the Modern Therapeutic Era: One Size No Longer Fits All

PeerView Clinical Pharmacology CME/CNE/CPE Audio Podcast

Go online to PeerView.com/YEM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The therapeutic landscape of bladder cancer has undergone a significant transformation with the addition of immune checkpoint inhibitors to the treatment armamentarium. In addition, the research on actionable targets has led to regulatory approval of the FGFR-targeted therapy, erdafitinib, for FGFR mutation–positive bladder tumors, as well as the antibody–drug conjugates enfortumab vedotin and sacituzumab govitecan. Further, novel bladder preservation opportunities and important combination approaches expand the therapeutic capacity across the disease spectrum available to patients with bladder cancer. In this PeerView activity, a panel of leading bladder cancer experts pairs important analyses of the latest evidence on a new generation of therapeutics with practical insights that can be used to guide therapeutic decision-making in the clinic. This CME/MOC-certified activity will highlight strategies for optimal care of patients with bladder cancer in light of current evidence on and indications for the use of immune, targeted, and antibody-based therapies and guidance on safely integrating these agents into treatment plans. Using patient cases drawn from clinical practice and interactivity that allows participants to see how their treatment choices compare with their colleagues, the faculty will address the mechanistic rationale for these new therapies, therapeutic decision-making, and AE mitigation strategies. Upon completion of this activity, participants should be better able to: Synthesize new evidence on multi-faceted strategies for bladder cancer management based on modern immunotherapeutic agents, small molecule targeted therapies, and antibody–drug conjugates, among others; Integrate novel and emerging therapeutic approaches into personalized treatment plans for patients with bladder cancer, considering the available evidence, current guidelines, and principles of multidisciplinary and patient-centered care; and Implement evidence- and team-based management protocols to address the unique suite of adverse events associated with novel therapeutics for bladder cancer